FIELD: biotechnology and medicine.
SUBSTANCE: invention relates to biotechnology and medicine. The proposed is a binding molecule containing an NGF antagonist domain (nerve growth factor) and a TNFα antagonist domain (tumor necrosis factor alpha), where the NGF antagonist is an anti-NGF antibody or its antigen-binding fragment, and where the anti-NGF antibody or its fragment contains a severe variable domain. chain (VH domain) containing a set of hypervariable regions (CDR) HCDR1, HCDR2, HCDR3, and a light chain variable domain (VL domain) containing a set of CDRs LCDR1, LCDR2 and LCDR3, and HCDR1 has the amino acid sequence of SEQ ID NO: 4 , HCDR2 has the amino acid sequence of SEQ ID NO: 5, HCDR3 has the amino acid sequence of any of SEQ ID NO: 6, 11, or 12, LCDR1 has the amino acid sequence of SEQ ID NO: 8, LCDR2 has the amino acid sequence of SEQ ID NO: 9, and LCDR3 has the amino acid sequence the sequence of SEQ ID NO: 10.
EFFECT: administration of an NGF antagonist and a TNFα antagonist of the present invention can control pain in a subject more effectively.
17 cl, 17 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
